Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-18
2011-11-29
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S282000
Reexamination Certificate
active
08067427
ABSTRACT:
A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties.
REFERENCES:
patent: 1 481 678 (2004-12-01), None
patent: WO 98/13354 (1998-04-01), None
patent: WO 01/32651 (2001-05-01), None
Bates, David: “ZD-6474 AstraZeneca.” Current Opinion in Investigational Drugs, 4(12): 1468-1472 (2003).
Lerk CF et al., “Effect of microcrystalline cellulose on liquid penetration in and disintegration of directly compressed tablets”, J. Pharm. Sci., Feb. 1979, 68(2), 205-11.
AstraZeneca AB
Morgan & Lewis & Bockius, LLP
Ward Paul V.
LandOfFree
Pharmaceutical compositions comprising ZD6474 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising ZD6474, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising ZD6474 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298700